A. Floquet

发表

Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.

O. Trédan, F. Gernier, A. Gompel, 2021, Gynecologic oncology.

Sustainable Agriculture and Innovation Adoption in a Small-Scale Food Production System: the Case of Yam in Rotation with Intercropping Mucuna pruriens var utilis and Maize in the Guinea-Sudan Zone of Benin

L. Parrot, B. Sinsin, A. Floquet, 2016 .

Thermomechanical Behavior of Multilayered Media: Theory

B. Villechaise, A. Floquet, J. Leroy, 1989 .

Thermomechanical Behavior of Multilayered Media: Results

B. Villechaise, A. Floquet, J. Leroy, 1990 .

Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.

B. Weber, I. Ray-Coquard, A. Floquet, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Oza, J. Ledermann, T. Park-Simon, 2021, The Lancet. Oncology.

Treatment at Relapse (Surgery and Systemic Treatments)

A. Floquet, J. Pfisterer, 2017 .

Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study

V. Brouste, S. Mathoulin-Pélissier, A. Floquet, 2013, Cancer Chemotherapy and Pharmacology.

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

B. Monk, I. Vergote, S. Pignata, 2019, Gynecologic oncology.

CLINICAL STUDIES

P. Gerszten, L. Mauriac, A. Floquet, 2004 .

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.

C. Haie-meder, F. Bertucci, B. Weber, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing

M. Bihoreau, N. Servant, D. Stoppa-Lyonnet, 2018, International journal of cancer.

Making sense of innovation processes in african smallholder agricullture

B. Triomphe, A. Floquet, C. Almekinders, 2016 .

Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers.

C. Genestie, R. Rouzier, F. Guyon, 2019, European journal of cancer.

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.

P. Viens, A. Floquet, A. Gonçalves, 2008, Gynecologic oncology.

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.

Jae-Weon Kim, B. Monk, I. Vergote, 2015, Gynecologic oncology.

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

O. Trédan, F. Gernier, E. Kalbacher, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms

F. Guyon, Gaëlle Pérot, I. Soubeyran, 2019, Modern Pathology.

Clinical impact of extensive molecular profiling in advanced cancer patients

I. Soubeyran, Y. Laizet, M. Toulmonde, 2017, Journal of Hematology & Oncology.

[Fibrolipomatous hamartoma of the peripheral nerves. Anatomico-clinical study of 5 cases, including 2 with ultrastructural study].

A. Floquet, O. Morel, M. Merle, 1987, Annales de pathologie.

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

R. Kimmig, L. Elit, G. Scambia, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.

D. Berton, F. Guyon, N. Radosevic-Robin, 2020, Gynecologic oncology.

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

D. Berton, G. Baron, A. Floquet, 2021, Frontiers in Pharmacology.

Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network

I. Ray-Coquard, A. Bats, M. Le Frère-Belda, 2022, Cancers.

Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery

F. Guyon, V. Brouste, A. Floquet, 2014, Annals of Surgical Oncology.

Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?

F. Guyon, V. Brouste, A. Floquet, 2011, European journal of obstetrics, gynecology, and reproductive biology.

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

J. Wanders, F. Caponigro, A. Floquet, 2004, Investigational New Drugs.

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).

B. Monk, I. Vergote, S. Pignata, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis

L. Mauriac, A. Floquet, N. Houédé, 2007, British Journal of Cancer.

Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy

M. Piccart, I. Vergote, P. Willemse, 2003, International Journal of Gynecologic Cancer.

Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

I. Ray-Coquard, A. Floquet, D. Berton‐Rigaud, 2019, Journal of Clinical Oncology.

A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients

F. Pinguet, M. Campone, A. Floquet, 2009, Clinical Cancer Research.

Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)

F. Guyon, I. Treilleux, I. Ray-Coquard, 2020, Cancers.

Les entreprises sociales entre repli et rançonnement : analyse comparative multisectorielle au Bénin (Afrique de l'Ouest) Contribution à la cinquième conférence de l'ISTR « "Transforming Civil Society, Citizenship and Governance: The Third Sector in an Era of Global (Dis)Order"

A. Floquet, Développement Communal, 2002 .

Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials.

Parker, L. Stewart, M. Tattersall, 2003, European journal of cancer.

355 Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients

C. Genestie, A. Paci, C. Balleyguier, 2021, Journal for ImmunoTherapy of Cancer.

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

V. Gebski, M. Dimopoulos, I. Vergote, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy

M. Piccart, I. Vergote, P. Willemse, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.

L. weiswald, A. Leary, E. Kalbacher, 2022, Gynecologic oncology.

[Prognostic impact of tumour volume and lymph node involvement in intermediate stage T1b1 to T2b cancer of the uterine cervix].

F. Guyon, V. Brouste, A. Floquet, 2009, Bulletin du cancer.

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2021, The Lancet. Oncology.

Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.

D. Berton, D. Spaeth, I. Ray-Coquard, 2022, Gynecologic oncology.

Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.

I. Ray-Coquard, A. Floquet, F. Joly, 2012, Anticancer research.

[Advanced endometrial carcinoma: primary debulking surgery or neoadjuvant chemotherapy?].

F. Guyon, A. Floquet, E. Stoeckle, 2012, Bulletin du cancer.

Lymph Node Involvement in Epithelial Ovarian Cancer: Sites and Risk Factors in a Series of 355 Patients

F. Guyon, V. Brouste, G. MacGrogan, 2009, International Journal of Gynecologic Cancer.

Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer

G. MacGrogan, V. Picot, A. Floquet, 2003, International Journal of Gynecologic Cancer.

Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer

F. Guyon, A. Floquet, G. Ferron, 2022, International Journal of Gynecological Cancer.

EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.

M. Mouret-Reynier, V. D’Hondt, A. Floquet, 2019, Journal of Clinical Oncology.

CETUXICOL, a phase II trial randomizing standard treatment with or without cetuximab in primary cervical cancer treatment.

P. Petrow, F. Guyon, X. Sastre, 2012 .

This is a repository copy of A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line

Robin L. Jones, I. Ray-Coquard, B. Seddon, 2020 .

A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.

R. Rouzier, F. Guyon, P. Colombo, 2014 .

A Randomized Study of Bolus Fluorouracil Plus Folinic Acid Versus 21‐Day Fluorouracil Infusion Alone or in Association with Cyclophosphamide and Mitomycin C in Advanced Colorectal Carcinoma

C. Marsault, P. Quétin, A. Floquet, 1995, American journal of clinical oncology.

Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors

C. Genestie, F. Guyon, F. Chibon, 2018, Modern Pathology.

Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.

R. Rouzier, P. Colombo, I. Ray-Coquard, 2022, Gynecologic oncology.

First-Line Capecitabine Monotherapy for Slowly Progressing Metastatic Breast Cancer: Do We Need Aggressive Treatment?

V. Brouste, L. Mauriac, A. Floquet, 2009, Oncology.

Efficacy and tolerability of the ifosfamide–epirubicin combination in relapsed ovarian cancer

A. Floquet, F. Joly, D. Lebrun, 2004, International Journal of Gynecologic Cancer.

Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database

R. Rouzier, I. Ray-Coquard, A. Floquet, 2022, Cancers.

Biomarkers Associated with Lymph Nodal Metastasis in Endometrioid Endometrial Carcinoma

F. Guyon, C. Lucchesi, I. Soubeyran, 2022, Cancers.

Nutrients Budgets of the Sedentary Yam-Based Cropping Systems with Herbaceous Legumes in the Guinea-Sudan Transition Zone of Benin

B. Sinsin, A. Floquet, R. Maliki, 2019 .

Sedentary yam-based cropping systems in West Africa: Benefits of the use of herbaceous cover-crop legumes and rotation—lessons and challenges

B. Sinsin, A. Floquet, R. Maliki, 2017 .

Dry Matter Production, Nutrient Cycled and Removed, and Soil Fertility Changes in Yam-Based Cropping Systems with Herbaceous Legumes in the Guinea-Sudan Zone of Benin

É. Malézieux, P. Vernier, B. Sinsin, 2016, Scientifica.

Agronomic and Economic Performance of Yam-Based Systems with Shrubby and Herbaceous Legumes Adapted by Smallholders

B. Sinsin, A. Floquet, R. Maliki, 2012 .

Evaluating Yam-Based Cropping Systems Using Herbaceous Leguminous Plants in the Savannah Transitional Agroecological Zone of Benin

B. Sinsin, A. Floquet, R. Maliki, 2012 .

Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.

A. Floquet, J. Lotz, L. Gladieff, 2022, Gynecologic oncology.

Socio-economic and ecological outcomes of community based forest management: A case study from Tobé-Kpobidon forest in Benin, Western Africa

A. Floquet, A. Assogbadjo, V. Salako, 2016 .

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Anne Floquet, Andrew R Allen, James X. Sun, 2017, The Lancet. Oncology.

Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study.

O. Trédan, M. Mouret-Reynier, V. D’Hondt, 2022, The Lancet. Healthy longevity.

Prospects for a Geographical Indication (GI): Evaluation of the Willingness to Pay (WTP) of Two Food Products: Peanut Oil (Agonlinmi) and Wafers (Kwlikwli) of the Agonlin Areaâ€™s of Benin

Anne Floquet, Roch Mongbo, A. Floquet, 2016 .

[Ultrastructural study of the liver after treatment with perhexiline maleate].

A. Floquet, J. Sérot, G. Grignon, 1977, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.

C. Balleyguier, A. Leary, J. Droz, 2014, European journal of cancer.

SMARCA4 (BRG1) Loss of Expression Is a Useful Marker for the Diagnosis of Ovarian Small Cell Carcinoma of the Hypercalcemic Type (Ovarian Rhabdoid Tumor): A Comprehensive Analysis of 116 Rare Gynecologic Tumors, 9 Soft Tissue Tumors, and 9 Melanomas

F. Guyon, J. Coindre, G. MacGrogan, 2015, The American journal of surgical pathology.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Gabe S. Sonke, Anne Floquet, Kathleen Moore, 2018, The New England journal of medicine.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

James X. Sun, A. Tinker, D. Bowtell, 2017, Cancer discovery.

Kondrashova, O. et al. (2017) Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer

Swisher, James X. Sun, A. Tinker, 2017 .

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

James X. Sun, A. Oza, D. Provencher, 2017, The Lancet.

Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions

F. Guyon, F. Chibon, P. Terrier, 2015, Modern Pathology.

MED12 Alterations in Both Human Benign and Malignant Uterine Soft Tissue Tumors

F. Chibon, P. Lagarde, Gaëlle Pérot, 2012, PloS one.

Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome

P. Gestraud, E. Berns, P. Hillemanns, 2019, EBioMedicine.

Gene‐ and pathway‐level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility

E. Barillot, P. Guénel, T. Truong, 2020, International journal of cancer.

234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

M. Friedlander, C. Aghajanian, A. Leary, 2020, Annals of Oncology.

How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors

A. Floquet, F. Joly, P. Berthet, 2020, Therapeutic advances in medical oncology.

Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation

D. Stoppa-Lyonnet, S. Mazoyer, F. Damiola, 2021, Breast cancer research : BCR.

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

I. Treilleux, I. Ray-Coquard, E. Kalbacher, 2017, British Journal of Cancer.

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

B. Weber, I. Ray-Coquard, A. Floquet, 2013, British Journal of Cancer.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.

I. Vergote, S. Pignata, I. Ray-Coquard, 2020, JAMA oncology.

Networking for ovarian rare tumors: a significant breakthrough improving disease management

N. Chiannilkulchai, C. Genestie, F. Penault-Llorca, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocol

F. Guyon, A. Floquet, M. Kind, 2021, International Journal of Gynecological Cancer.

Prognostic Factors in Early-Stage Leiomyosarcoma of the Uterus

F. Collin, L. Guillou, A. Leroux, 2009, International Journal of Gynecologic Cancer.

A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)

Robin L. Jones, P. Casali, I. Ray-Coquard, 2020, International Journal of Gynecological Cancer.

Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group

J. Blay, F. Bertucci, S. Salas, 2019, International Journal of Gynecologic Cancer.

LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS.

B. Weber, A. Floquet, F. Selle, 2013 .

733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study

O. Trédan, A. Leary, A. Floquet, 2021, Annals of Oncology.

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).

J. Blay, F. Collin, S. Piperno-Neumann, 2012, The oncologist.

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

A. Oza, Byoung-Gie Kim, M. Friedlander, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intra and juxtavagal paraganglia: A topographical, histochemical, and ultrastructural study in the human

A. Floquet, F. Plénat, P. Leroux, 1988, The Anatomical record.

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

Chun-Fang Xu, T. Johnson, J. Chan, 2016, BMC Medical Ethics.

Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).

I. Treilleux, I. Ray-Coquard, O. Trédan, 2021, Gynecologic oncology.

GENESIS: a French national resource to study the missing heritability of breast cancer

D. Stoppa-Lyonnet, O. Sinilnikova, S. Mazoyer, 2016, BMC Cancer.

726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

B. Monk, H. Mackay, D. Miller, 2021, Annals of Oncology.

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

P. Petrow, I. Bièche, B. Weber, 2015, Clinical Cancer Research.

[Primary management of endometrial carcinoma. Joint recommendations of the French society of gynecologic oncology (SFOG) and of the French college of obstetricians and gynecologists (CNGOF)].

E. Darai, P. Crochet, A. Floquet, 2017, Gynecologie, obstetrique, fertilite & senologie.

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

F. Bertucci, M. Toulmonde, A. Le Cesne, 2015, The Lancet. Oncology.

Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women.

G. MacGrogan, L. Mauriac, A. Floquet, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

O. Trédan, F. Gernier, E. Kalbacher, 2019 .

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma

M. Friedlander, I. Ray-Coquard, B. Seddon, 2014, International Journal of Gynecologic Cancer.

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

F. Pinguet, J. Mazières, D. Concordet, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1

A. Oza, M. Friedlander, Byoung-Gie Kim, 2021, Gynecologic Oncology.

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

A. Italiano, J. Bonneterre, M. Campone, 2018, PloS one.

[Management of the nodal disease in vulvar cancers. The ESGO guidelines].

F. Guyon, A. Floquet, D. Querleu, 2019, Bulletin du cancer.

GREB1‐CTNNB1 fusion transcript detected by RNA‐sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): A novel CTNNB1 rearrangement

F. Guyon, F. Chibon, Gaëlle Pérot, 2019, Genes, chromosomes & cancer.

Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.

R. Rouzier, P. Colombo, I. Ray-Coquard, 2021, Gynecologic oncology.

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer

J. Coindre, G. MacGrogan, S. Mathoulin-Pélissier, 2003, British Journal of Cancer.

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

F. Bertucci, M. Toulmonde, A. Le Cesne, 2021, ESMO open.

The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas

F. Guyon, F. Chibon, Gaëlle Pérot, 2019, Clinical Cancer Research.

Pulsed-dose-rate brachytherapy for uterine cervix carcinoma: 10 years of experience with 226 patients at a single institution.

F. Guyon, V. Brouste, A. Floquet, 2013, Brachytherapy.

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

A. Oza, J. Ledermann, T. Park-Simon, 2020 .

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

C. Schade-Brittinger, F. Marmé, I. Vergote, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

S. Rodenhuis, E. Barillot, A. Nicolas, 2020, British Journal of Cancer.

A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.

F. Pinguet, A. Floquet, M. Etienne-Grimaldi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer

P. Gestraud, E. Berns, R. Rouzier, 2020, EBioMedicine.

YWHAE rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas: genetic and pathological correlations

F. Guyon, F. Chibon, J. Coindre, 2013, Modern Pathology.

Functional decline in older patients with cancer receiving first-line chemotherapy.

A. Ravaud, S. Mathoulin-Pélissier, A. Floquet, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of early death risk in older patients treated with first-line chemotherapy for cancer.

A. Ravaud, V. Brouste, A. Floquet, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

“Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”

I. Ray-Coquard, F. Gernier, E. Kalbacher, 2021, BMC Cancer.

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS).

G. MacGrogan, L. Mauriac, A. Floquet, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Fractionated radiation therapy in the treatment of stage III and IV cerebello-pontine angle neurinomas: preliminary results in 20 cases.

A. Floquet, J. Guérin, J. Bébéar, 1992, International journal of radiation oncology, biology, physics.

Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).

C. Genestie, D. Berton, I. Ray-Coquard, 2020, Gynecologic oncology.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

C. Genestie, R. Rouzier, F. Guyon, 2018, Bulletin du cancer.

Fretting: Load Carrying Capacity of Wear Debris

Yves Berthier, A. Floquet, Maurice Godet, 1984 .

The Challenge of Improving Soil Fertility in Yam Cropping Systems of West Africa

V. K. Hgaza, J. Six, D. Barjolle, 2017, Front. Plant Sci..

Contact Temperature in Dry Bearings. Three Dimensional Theory and Verification

D. Play, A. Floquet, A. Floquet, 1981 .

[First surgery followed by vaginal curietherapy in small-volume uterine cervix cancer: an alternative to the association of uterovaginal curietherapy and surgery].

A. Floquet, A. Avril, E. Bussières, 2002, Cancer Radiothérapie.

Applying Ostrom’s institutional analysis and development framework to soil and water conservation activities in north-western Ethiopia

N. Haregeweyn, A. Tsunekawa, E. Adgo, 2018 .

Surgery, Chemotherapy, and Radiotherapy for Gynaecological Cancer

A. Floquet, K. Pantazis, K. Dinas, 2021 .

Land use and farming systems in Benin

Anne Floquet, Karl Stahr, K. Stahr, 2003 .

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.

I. Treilleux, E. Kalbacher, A. Floquet, 2020, Gynecologic oncology.

Retrospective analysis of chemotherapy choices and overall survival according to treatment in 96 patients >75 years old with metastatic breast cancer

V. Brouste, L. Mauriac, A. Floquet, 2008 .

Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.

C. Genestie, S. Broutin, C. Balleyguier, 2021 .

Potentials and perils on periurban agriculture in a West African coastal region.

A. Floquet, 1999 .

PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.

D. Berton, I. Ray-Coquard, M. Moubarak, 2023, Gynecologic oncology.

2755 First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU)

I. Ray-Coquard, A. Floquet, P. Follana, 2015 .

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.

R. Rouzier, P. Colombo, E. Kalbacher, 2017, European journal of cancer.

Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.

C. Genestie, D. Berton, F. Guyon, 2023, Gynecologic oncology.

Combination of finite element and integral transform techniques in a heat conduction quasi‐static problem

A. Floquet, F. Colin, 1986 .

Improved techniques for finite element analysis of sliding surface temperatures

F. E. Kennedy, A. Floquet, F. Colin, 1984 .

Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer.

F. Bertucci, S. Chevret, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.

S. Mathoulin-Pélissier, X. Paoletti, B. Geoerger, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study

F. Durrieu, S. Mathoulin-Pélissier, I. Soubeyran, 2023, International journal of environmental research and public health.

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

Jae-Weon Kim, A. Oza, M. Friedlander, 2021, Gynecologic oncology.

Onapristone (ONA) in progesterone receptor (PR)-expressing tumors: Efficacy and biomarker results of a dose-escalation phase 1 study.

A. Italiano, J. Bonneterre, M. Campone, 2015 .

Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.

D. Berton, I. Ray-Coquard, A. Floquet, 2023, Gynecologic oncology.

811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

A. Oza, M. Friedlander, C. Aghajanian, 2020 .

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

A. Reuss, A. Okamoto, S. Lheureux, 2019, Journal of Clinical Oncology.

Intra-observer agreement in single and joint double readings of contrast-enhanced breast MRI screening for women with high genetic breast cancer risks

A. Floquet, M. Longy, M. Asad-Syed, 2013 .

973PA GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC)

A. Leary, E. Kalbacher, A. Floquet, 2017 .

Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.

J. Blay, S. Mathoulin-Pélissier, M. Toulmonde, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

LBA67 TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas

J. Blay, S. Mathoulin-Pélissier, M. Toulmonde, 2020 .

Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.

B. Monk, Chun-Fang Xu, T. Johnson, 2014 .

Pooled analysis of onapristone extended release (ONA ER) in metastatic cancer patients (pts): A review of liver safety.

P. Watkins, A. Italiano, J. Bonneterre, 2019, Journal of Clinical Oncology.

INTRAPERITONEAL (IP) CISPLATIN (P) VERSUS NO FURTHER TREATMENT: 8 YEAR-RESULTS OF AN EORTCGCG RANDOMIZED PHASE III STUDY IN OVARIAN CANCER (O.C.) PATIENTS (PTS) WITH A PATHOLOGICALLY COMPLETE REMISSION (PCR) AFTER P-BASED INDUCTION CHEMOTHERAPY (CT) AND CYTOREDUCTIVE SURGERY

M. Piccart, I. Vergote, P. Willemse, 2003, International Journal of Gynecologic Cancer.

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.

A. Oza, M. Friedlander, C. Aghajanian, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2019, Journal of Clinical Oncology.

Agricultural productivity and food security of agricultural households in Benin : heterodox approach

J. Yabi, A. Floquet, G. Biaou, 2020 .

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients.

C. Haie-meder, B. Weber, I. Ray-Coquard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse

P. Colombo, I. Ray-Coquard, A. Floquet, 2023, International Journal of Gynecological Cancer.

The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.

J. Blay, I. Treilleux, I. Ray-Coquard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

A. Floquet, D. Cibula, F. Heitz, 2022, Annals of Oncology.

Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study

D. Berton, A. Floquet, L. Gladieff, 2023, Drugs - Real World Outcomes.

Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials

Parker, L. Stewart, M. Tattersall, 2003 .

827P First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc)

Arianne C. Richard, A. Floquet, M. Urbieta, 2020 .

Multicentre randomized phase II trial of olaparib as maintenance therapy in platinum-sensitive advanced endometrial carcinoma: The GINECO-UTOLA study.

B. Asselain, K. Leroy, A. Leary, 2020 .

EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment

R. Rouzier, T. Petit, I. Ray-Coquard, 2019, International Journal of Gynecological Cancer.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What Does an Inventory of Recent Innovation Experiences Tell Us About Agricultural Innovation in Africa?

B. Triomphe, H. Hocdé, T. Crane, 2013 .

Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy.

F. Guyon, S. Nougaret, A. Floquet, 2021, Diagnostic and interventional imaging.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

C. Genestie, F. Guyon, C. Rousset-Jablonski, 2018, Bulletin du cancer.

C. Haie-meder, F. Bertucci, I. Ray-Coquard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

M. Mouret-Reynier, N. Colombo, A. Floquet, 2021, Gynecologic oncology.

Effect of high-dose chemotherapy with autologous stem cell rescue (HDC-aSCR) on outcome in ovarian small-cell carcinoma, hypercalcemic type (SCCOHT): Prospective series from the French Rare Gynecologic Malignant Tumors Network (TMRG).

C. Genestie, D. Berton, I. Ray-Coquard, 2020 .

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

D. Katsaros, F. Marmé, M. Yunokawa, 2023, The Lancet.

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.

A. Oza, M. Friedlander, C. Aghajanian, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.

P. Fumoleau, A. Floquet, C. Tourneau, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

F. Bertucci, M. Toulmonde, A. Le Cesne, 2015, The Lancet. Oncology.

Sustainable Agroforestry Adoption in a Small-Scale Food Production System: the Case of Yam in Rotation with the Intercropping Gliricidia Sepium and Herbaceous in the Guinea-Sudan Zone of Benin

L. Parrot, B. Sinsin, A. Floquet, 2019 .

Heterogeneous welfare effect of cotton pricing on households in Benin

A. Floquet, D. Alia, Épiphane Adjovi, 2017 .

Joint learning to enhance innovation systems in African agriculture

Bernard Triomphe, Todd A. Crane, Ann Waters-Bayer, 2012 .